Thrombosis in Japanese patients with Fabry disease

被引:15
作者
Utsumi, Kouichi [1 ]
Ueda, Kae
Watanabe, Megumi
Sakamaki, Masanori
Arii, Kazumasa
Yamazaki, Mineo
Komaba, Yuichi
Katsura, Ken-ichiro
Iino, Yasuhiko
Katayama, Yasuo
机构
[1] Nippon Med Sch, Dept Internal Med, Div Neurol, Bunkyo Ku, Tokyo 1138603, Japan
关键词
alpha-Galactosidase A; Globotriaosylceramide; Strokes; Thrombophlebitis; Central retinal artery occlusion; Enzyme replacement therapy; HUMAN ALPHA-GALACTOSIDASE; REPLACEMENT THERAPY;
D O I
10.1016/j.jns.2009.02.319
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fabry disease is an X-linked lysosomal storage disease resulting from deficient activity of the enzyme alpha-galactosidase (alpha-Gal) A. It has been postulated that the accumulation of globotriaosylceramide in the endothelial cells of blood vessels may lead to thrombosis of the brain and other tissues. Recently, enzyme replacement therapy (ERT) for Fabry disease is available. A high incidence of thrombotic accidents in Fabry disease has been postulated. However, a systemic study on thrombosis in cases of Fabry disease has not been undertaken. To clarify the incidence of thrombosis in Fabry disease, we screened 65 patients with Fabry disease (49 hemizygotes and 16 heterozygotes) from 39 unrelated Japanese families. We found that ten patients with Fabry disease (7 hemizygous males and 3 heterozygous females) had experienced thrombotic accidents, under 45-years-old in 8 cases. These 10 patients showed the gene mutations of classical Fabry disease. Nine of these thrombotic patients developed brain infarctions, one man who had the complication of recurrent thrombophlebitis, and the remaining woman showed central retinal artery occlusion and thrombophlebitis. We demonstrated a high incidence of thrombosis in Fabry disease (15%). ERT should be performed in patients not only in hemizygous males but also in heterozygous females and started at their early ages. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:83 / 85
页数:3
相关论文
共 12 条
[1]  
DEGEABA T, 2000, ANN NEUROL, V47, P229
[2]  
Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733
[3]   Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. [J].
Eng, CM ;
Guffon, N ;
Wilcox, WR ;
Germain, DP ;
Lee, P ;
Waldek, S ;
Caplan, L ;
Linthorst, GE ;
Desnick, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) :9-16
[4]   Female heterozygous patient with Fabry's disease with renal accumulation of trihexosylceramide detected with a monoclonal antibody [J].
Fukushima, M ;
Tsuchiyama, Y ;
Nakato, T ;
Yokoi, T ;
Ikeda, H ;
Yoshida, S ;
Kusumoto, T ;
Itoh, K ;
Sakuraba, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (06) :952-955
[5]   HUMAN ALPHA-GALACTOSIDASE GENE-EXPRESSION - SIGNIFICANCE OF 2 PEPTIDE REGIONS ENCODED BY EXONS 1-2 AND 6 [J].
ISHII, S ;
KASE, R ;
SAKURABA, H ;
FUJITA, S ;
SUGIMOTO, M ;
TOMITA, K ;
SEMBA, T ;
SUZUKI, Y .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1994, 1204 (02) :265-270
[6]   DIFFERENTIAL ASSAY FOR LYSOSOMAL ALPHA-GALACTOSIDASES IN HUMAN-TISSUES AND ITS APPLICATION TO FABRYS-DISEASE [J].
MAYES, JS ;
SCHEERER, JB ;
SIFERS, RN ;
DONALDSON, ML .
CLINICA CHIMICA ACTA, 1981, 112 (02) :247-251
[7]   Cerebrovascular complications of Fabry's disease [J].
Mitsias, P ;
Levine, SR .
ANNALS OF NEUROLOGY, 1996, 40 (01) :8-17
[8]  
SAKURABA H, 1986, CLIN GENET, V29, P276
[9]   Enzyme replacement therapy in Fabry disease - A randomized controlled trial [J].
Schiffmann, R ;
Kopp, JB ;
Austin, HA ;
Sabnis, S ;
Moore, DF ;
Weibel, T ;
Balow, JE ;
Brady, RO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2743-2749
[10]   Recurrent strokes in a young adult patient with Fabry's disease [J].
Tanaka, N ;
Utsumi, K ;
Seta, T ;
Usuda, K ;
Komaba, Y ;
Katsumata, T ;
Katsura, KI ;
Sakamoto, S ;
Katayama, Y .
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (06) :486-487